ALK announced that the U.S. FDA expanded its indication of Odactra for the treatment of house dust mite-induced allergic rhinitis, with or without conjunctivitis, to now include children ages 5 through 11 years, in addition to patients 12 through 65 years of age.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AKBLF: